Lantern Pharma Inc. (LTRN)
Lantern Pharma Statistics
Share Statistics
Lantern Pharma has 10.78M shares outstanding. The number of shares has increased by 0.24% in one year.
Shares Outstanding | 10.78M |
Shares Change (YoY) | 0.24% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 23.23% |
Shares Floating | 8.03M |
Failed to Deliver (FTD) Shares | 1.81K |
FTD / Avg. Volume | 2.24% |
Short Selling Information
The latest short interest is 259.35K, so 2.4% of the outstanding shares have been sold short.
Short Interest | 259.35K |
Short % of Shares Out | 2.4% |
Short % of Float | 2.74% |
Short Ratio (days to cover) | 10.31 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -3.02. Lantern Pharma's PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -3.02 |
PS Ratio | 0 |
Forward PS | 1.2 |
PB Ratio | 0 |
P/FCF Ratio | -1.93 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lantern Pharma.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.
Current Ratio | 5.83 |
Quick Ratio | 5.83 |
Debt / Equity | 0 |
Debt / EBITDA | 0 |
Debt / FCF | -0.01 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-865.88M |
Employee Count | 24 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -32.9% in the last 52 weeks. The beta is 1.62, so Lantern Pharma's price volatility has been higher than the market average.
Beta | 1.62 |
52-Week Price Change | -32.9% |
50-Day Moving Average | 3.76 |
200-Day Moving Average | 3.83 |
Relative Strength Index (RSI) | 55.76 |
Average Volume (20 Days) | 80.8K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -22.22B |
Net Income | -20.78B |
EBITDA | -22.22B |
EBIT | n/a |
Earnings Per Share (EPS) | -1930.92 |
Balance Sheet
The company has 7.51M in cash and 243.66K in debt, giving a net cash position of 7.27M.
Cash & Cash Equivalents | 7.51M |
Total Debt | 243.66K |
Net Cash | 7.27M |
Retained Earnings | -76.03B |
Total Assets | 25.57M |
Working Capital | 20.92M |
Cash Flow
In the last 12 months, operating cash flow was -17.81M and capital expenditures 0, giving a free cash flow of -17.83M.
Operating Cash Flow | -17.81M |
Capital Expenditures | 0 |
Free Cash Flow | -17.83M |
FCF Per Share | -1.66 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
LTRN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for LTRN is $25, which is 592.5% higher than the current price. The consensus rating is "Hold".
Price Target | $25 |
Price Target Difference | 592.5% |
Analyst Consensus | Hold |
Analyst Count | 2 |
Scores
Altman Z-Score | -0.96 |
Piotroski F-Score | 2 |